2023 Conference Agenda

Monday, April 17, 2023

7:30 AM
Registration/Continental Breakfast
8:15 AM
Chairperson's Opening Remarks
Mollie Roth, JD, Chairperson, The Annual Translational Microbiome Conference
8:30 AM

Presentation to be Announced Soon
Heidi Hau, Ph.D., VP, Scientific Affairs & Partnerships, Clinical Microbiomics

9:00 AM

Establishing the 1st WHO International Reference Reagents for Microbiome Analysis
Effective standardisation is essential to translational research and product development. Reference reagents allow for commutability of results across clinical studies and give assurances of quality for manufactured products or diagnostic assays. The MHRA is leading multiple WHO Collaborative Studies to establish a range of reference reagents suitable for standardising microbiome methodologies. These include site-specific DNA and whole-cell reagents for standardisation of NGS, bioinformatics, and DNA extractions. Importantly, we have developed a reporting framework that can be used in conjunction with developed reagents to allow for meaningful interpretation of the results. Here, we will discuss the development of these reagents and present results from the WHO international collaborative study which run throughout 2021 with 23 participants from 11 countries across Asia, Europe, North America and Australia, testing multiple different methodologies and bioinformatics pipelines for shotgun and 16S rRNA amplicon sequencing, establishing the 1st WHO International Reference Reagents for microbiome analysis.
Chrysi Sergaki, Ph.D. , Principal Investigator, Microbiome Group Group Leader, Alveolus Bio, Director, Pulmonary Microbiome Lab, Medicines & Healthcare Products Regulatory Agency, United Kingdom

9:30 AM

(Provisional Title) The Impact of the Microbiome on Statins
Noa Rappaport, Ph.D., Senior Research Scientist, The Hood-Price Lab for Systems Biomedicine, Institute for Systems Biology

10:00 AM
Refreshment/Networking/Poster-Viewing Break
10:30 AM

(Provisional Title) An Update on Clinical Trials to Date and a Report on Recent Clinical Data
Nikole Kimes, Ph.D., Founder, Siolta Therapeutics

11:00 AM

Modulating the Vaginal Microbiome for Women’s Health and Fertility
The talk will cover an update on the clinical trial of LACTIN-V for recurrent bacterial vaginosis, findings, and post hoc analysis. Also a short update on the FRESH study-South African Women at risk for HIV acquisition, and the FLIP-1 study for women at risk of Preterm birth.
Laurel Lagenaur, Ph.D., Senior Scientist, Osel

11:30 AM

Presentation to be Announced Soon
Kelle Moley, MD, VP, Science & Public Affairs, Ferring

12:00 PM

Luncheon

1:00 PM

Microbiome Medicine: Payors, Providers, and Patients
Microbiome management incorporated into disease preventive screening diagnostics, patient education, and health accountability as a standard practice of care.
Cassandra Isley, Chief Executive Officer, Microbiome Alliance for Disease Prevention

1:30 PM

Diet Intervention Study Impact
Emily Hollister, Ph.D., Director, R&D, Computational Biology, Diversigen

2:00 PM

Presentation to be Announced Soon
Leigh Frame, Ph.D., Associate Director, Resiliency & Well-Being Center, Program Director, Integrative Medicine, School of Medicine & Health Sciences, George Washington University

2:30 PM

The Impact of Diet and Antibiotics on Colorectal Cancer and Immunotherapy: A call for Intervention
From a clinical perspective, an individual’s diet has substantial impacts on the microbiome but current efforts to modify the microbiome to improve health through the use of probiotics have either failed and/or may hinder reconstitution of the microbiome after antibiotic exposure. This has significant impact given the impact of diet and antibiotics on risk for colorectal cancer, which has increased substantially worldwide, especially in the early onset timeframe. We posit that tumor genetic mutations even at very early stages impact the microbiome creating a pro-tumor feedback loop that benefits the tumor but not the host. There is potential for dietary interventions and/or fecal microbiota therapy to slow the emergence of cancer from non-cancer neoplasia in the gut with relevance to both hereditary and sporadic colorectal cancer at all ages. However, indiscriminate use of antibiotics also impact responses to immunotherapy, likely across many tumor types. In order to better understand this interaction, additional investment is needed in pragmatic translational clinical trials to manipulate the microbiome/metabolites to benefit the host to better refine potential preventatives and therapeutic approaches.
Cynthia L. Sears, MD, Bloomberg-Kimmel Professorship of Cancer Immunotherapy, Professor of Medicine, Johns Hopkins School of Medicine

3:00 PM

Refreshment/Networking/Poster-Viewing Break

3:30 PM
(Provisional Title) The Use of Oligosacchrides for Purposes Such as Immuno Oncologic Therapy
Matt Amicucci, Ph.D. , Chief Medical Officer, Biotia, Co-Founder, VP of Research & Development, BCD Bio
4:00 PM

(Provisional Title) Metatranscriptomics and Chronic Disease
Guru Banavar, Ph.D., Chief Technology Officer, Head of Discovery, Viome

4:30 PM

Cocktail Reception

About Us

Our events give attendees a conference experience that encompasses learning, networking and professional growth. We strive to facilitate connections. At our events, attendees, speakers, sponsors and exhibitors have opportunities to network and then to utilize those connections to further their professional goals. At Arrowhead Publishers, our focus is on bringing life sciences industry professionals together to help move research forward. Learn more about us at www.arrowheadpublishers.com.

Contact Us

Arrowhead Publishers & Conferences
PO Box 96
7730 Laredo Drive, #96
Chanhassen, MN 55317
866-945-0263
enquiries@arrowheadpublishers.com

PRIVACY POLICY

Organized By

Join Our Linked In Group & Twitter Feed